

No. 522

9 June 2006

No. 522

9 June 2006

<p><b>NO C13</b></p> <p><b>2005</b></p> <p><b>EXCLUSION OF CERTAIN MEDICINES FROM THE OPERATION OF CERTAIN PROVISIONS OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT NO 101 OF 1965)</b></p> <p>I, <b>Mandisa Hela, Registrar of Medicines</b>, acting by virtue of a delegation in terms of section 34A of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), hereby exclude in terms of Section 36 of Act 101 of 1965, on the unanimous recommendation of the members present at a meeting of the Medicine Control Council held on <b>25 November 2005</b> the medicines listed in the schedule hereto from the operation of the therein listed provisions of the regulations promulgated by Government Notice No. R.510 of 10 April 2003.</p> <p>.....</p> <p><b>MANDISA HELA</b> <b>REGISTRAR OF MEDICINES</b></p>	<p><b>NO C13</b></p> <p><b>2005</b></p> <p><b>UITSLUITING VAN SEKERE MEDISYNE VAN DIE TOEPASSING VAN SEKERE BEPALING VAN DIE WET 101 VAN 1965 (WET NR. 101 VAN 1965)</b></p> <p>Ek, <b>Mandisa Hela, Registrateur van Medisyne</b>, handelend kragtens 'n delegasie ingevolge artikel 34A van die Wet op Medisyne en Verwante Stowwe, 1965 (Wet 101 van 1965), en op eenparige aanbeveling van die lede van die Medisynebeheerraad teenwoordig in 'n vergadering gehou op <b>25 November 2005</b>, sluit hierby uit, kragtens Artikel 36 van Wet 101 van 1965, die medisyne in die Bylae hiervan vermeld van die toepassing van die daarinvermelde bepalings van die regulasies afgekondig by Goewermentskennisgewing No. R.510 van 10 April 2003, onderworpe aan die voorwaardes ingelys in the Bylae vermeld.</p> <p>.....</p> <p><b>MANDISA HELA</b> <b>REGISTRATEUR VAN MEDISYNE</b></p>
---	--

REGISTRATION NO/ REGISTRASIE NO	NAME OF MEDICINE/ NAAM VAN MEDISYNE	FORM OF PREPARATION/ BEREIDINGSVORM	PROVISIONS FROM WHICH EXCLUDED/ BEPALINGS WAARVAN UITGESLUIT	CONDITIONS OF EXCLUSION/ VOORWAARD ES VIR UITSLUITING	APPLICANT/ APPLIKANT
A38628	Sabax Adrenaline 1mg/ml	Injection	Regulation 8(1)(e): Bilingualism of the approved name of the active ingredient		Adcock Ingram Critical Care
01/3.1/1 03/3.1/2 03/3.1/3 03/3.1/4	Zubrin 30mg Zubrin 50mg Zubrin 100mg Zubrin 200mg	Tablet Tablet Tablet Tablet	Regulation 48 (2)(a): The wording "Veterinary Medicines" Regulation 48 (1)(o): Name of the holder of the certificate registration  And  And in terms of the provisions of Regulation 8(3) to allow the information to appear on the label of the immediate container label to be so included:  The wording: "For dogs only" "Mfd for Schering-Plough Animal Health" "Tepoxalin" (The name of the active ingredient will form part of the proprietary name of the product) Be authorised to include the wording "Access Initiative" on the label		Schering Plough Pty Ltd
A39/20.2.8/0088 A39/20.2.8/0089	Reyataz 150mg Reyataz 200mg	Capsules Capsules			Bristol-Myers Squibb
Q/20.2/92	Intramed Trichazole Infusion		Regulation 8(1)(c): Registration number provided that the exemption is only applicable to 13 batches: 32750, 32754, 32759, 32764, 32770, 32817, 32825, 33087, 33088, 33094, 33100, 33106, 33112		Bodene (Pty)Ltd